JP5872466B2 - 放射性核種含有ナノ粒子を製造するための封入方法 - Google Patents

放射性核種含有ナノ粒子を製造するための封入方法 Download PDF

Info

Publication number
JP5872466B2
JP5872466B2 JP2012519888A JP2012519888A JP5872466B2 JP 5872466 B2 JP5872466 B2 JP 5872466B2 JP 2012519888 A JP2012519888 A JP 2012519888A JP 2012519888 A JP2012519888 A JP 2012519888A JP 5872466 B2 JP5872466 B2 JP 5872466B2
Authority
JP
Japan
Prior art keywords
radionuclide
nanoparticle composition
group
vesicle
ionophore
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012519888A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012533523A5 (enExample
JP2012533523A (ja
Inventor
ルイザ ペーテルゼン，アンカトリーネ
ルイザ ペーテルゼン，アンカトリーネ
ラスムスン，パレ ヒーゼングラン
ラスムスン，パレ ヒーゼングラン
ヘンレクスン，ヨーナス ローセーヤ
ヘンレクスン，ヨーナス ローセーヤ
ケーア，アンドレーアス
ラース アナスン，トマス
ラース アナスン，トマス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigshospitalet
Danmarks Tekniske Universitet
Original Assignee
Rigshospitalet
Danmarks Tekniske Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigshospitalet, Danmarks Tekniske Universitet filed Critical Rigshospitalet
Publication of JP2012533523A publication Critical patent/JP2012533523A/ja
Publication of JP2012533523A5 publication Critical patent/JP2012533523A5/ja
Application granted granted Critical
Publication of JP5872466B2 publication Critical patent/JP5872466B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012519888A 2009-07-17 2010-07-16 放射性核種含有ナノ粒子を製造するための封入方法 Expired - Fee Related JP5872466B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA200900879 2009-07-17
DKPA200900879 2009-07-17
US30078210P 2010-02-02 2010-02-02
US61/300,782 2010-02-02
EP10152394.2 2010-02-02
EP10152394 2010-02-02
PCT/DK2010/050192 WO2011006510A1 (en) 2009-07-17 2010-07-16 Loading technique for preparing radionuclide and ionophore containing liposomes in which the ionophore is 2-hydroxyquionoline (carbostyril) or structurally related 2-hydroxyquinolines

Publications (3)

Publication Number Publication Date
JP2012533523A JP2012533523A (ja) 2012-12-27
JP2012533523A5 JP2012533523A5 (enExample) 2013-08-08
JP5872466B2 true JP5872466B2 (ja) 2016-03-01

Family

ID=43448962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012519888A Expired - Fee Related JP5872466B2 (ja) 2009-07-17 2010-07-16 放射性核種含有ナノ粒子を製造するための封入方法

Country Status (7)

Country Link
US (2) US8920775B2 (enExample)
EP (1) EP2453927B1 (enExample)
JP (1) JP5872466B2 (enExample)
AU (1) AU2010272957B2 (enExample)
CA (1) CA2768444A1 (enExample)
IN (1) IN2012DN01449A (enExample)
WO (1) WO2011006510A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5947807B2 (ja) 2010-12-14 2016-07-06 テクニカル ユニバーシティ オブ デンマークＴｅｃｈｎｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｄｅｎｍａｒｋ ナノ粒子組成物への放射性核種の封入
WO2013158803A1 (en) * 2012-04-17 2013-10-24 Merrimack Pharmaceuticals, Inc. Compositions and methods for non-invasive imaging
EP2922578B1 (en) * 2012-11-21 2018-12-12 Serene, Llc Tin-117m comprising somatostatin receptor binding compounds
ES2820734T3 (es) 2013-03-11 2021-04-22 Univ Wayne State Liposomas que comprenden criptandos de europio y su uso
US10781178B2 (en) 2015-08-12 2020-09-22 The General Hospital Corporation 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents
JP2019512484A (ja) * 2016-03-07 2019-05-16 メモリアル スローン ケタリング キャンサー センター 骨髄、細網内皮系、および／またはリンパ節を標的にする放射標識リポソームならびにその診断用および治療用使用の方法
WO2020055929A1 (en) * 2018-09-11 2020-03-19 Memorial Sloan Kettering Cancer Center Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use
US11478493B2 (en) * 2019-03-08 2022-10-25 University Of South Carolina Fabrication and application of a hetero-targeted nano-cocktail with traceless linkers
KR20230173150A (ko) 2021-04-20 2023-12-26 테라파워, 엘엘씨 Ac-225 생성용 티타니아 기반 발생기
EP4536278A4 (en) 2022-06-07 2026-08-12 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2710847B2 (ja) 1987-11-04 1998-02-10 ネクスター・フアーマシユーテイカルズ・インコーポレイテツド 中性子捕獲療法剤およびその製法
US5688488A (en) 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5525232A (en) * 1990-03-02 1996-06-11 The Liposome Company, Inc. Method for entrapment of cationic species in lemellar vesicles
JPH075561B2 (ja) * 1991-12-17 1995-01-25 工業技術院長 α−アミノ酸のジアミド誘導体
US5837282A (en) * 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US5945502A (en) * 1997-11-13 1999-08-31 Xerox Corporation Electroluminescent polymer compositions and processes thereof
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
DE10012782A1 (de) * 2000-03-16 2001-09-20 Boellhoff Gmbh Verbindungsanordnung zum Anbringen eines Befestigungselementes an einem Bauteil
WO2004082627A2 (en) * 2003-03-18 2004-09-30 Ethicon, Inc. ENZYME REPLACEMENT THERAPY WITH 17-β-HYDROXYSTEROID DEHYDROGENASE-TYPE 2
WO2004082626A2 (en) * 2003-03-18 2004-09-30 Ethicon, Inc. Aromatase inhibitor diagnosis and therapy
WO2006021008A2 (en) 2004-08-20 2006-02-23 Lind Stuart E Ionophores as cancer chemotherapeutic agents
CN101072588B (zh) * 2004-10-06 2012-11-28 不列颠哥伦比亚抗癌机构 用于治疗癌症的具有改善的药物保留的脂质体
GB0423565D0 (en) * 2004-10-22 2004-11-24 Algeta As Formulation
ITMI20050328A1 (it) 2005-03-03 2006-09-04 Univ Degli Studi Milano Composti peptidomimetrici e preparazione di derivati biologicamente attivi
WO2008105773A2 (en) * 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
TW200922630A (en) 2007-09-26 2009-06-01 Nat Health Research Institutes Liposome compositions useful for tumor imaging and treatment
WO2009140215A2 (en) * 2008-05-11 2009-11-19 Geraghty, Erin Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds
EP3424564A1 (en) * 2011-10-31 2019-01-09 Mallinckrodt LLC Combinational liposome compositions for cancer therapy

Also Published As

Publication number Publication date
AU2010272957B2 (en) 2016-03-03
AU2010272957A1 (en) 2012-03-08
US20150202336A1 (en) 2015-07-23
WO2011006510A1 (en) 2011-01-20
EP2453927A1 (en) 2012-05-23
US20120213698A1 (en) 2012-08-23
EP2453927B1 (en) 2019-05-15
IN2012DN01449A (enExample) 2015-06-05
US8920775B2 (en) 2014-12-30
EP2453927A4 (en) 2013-01-23
JP2012533523A (ja) 2012-12-27
CA2768444A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
JP5947807B2 (ja) ナノ粒子組成物への放射性核種の封入
EP3498308B1 (en) Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
JP2012533523A (ja) 放射性核種含有ナノ粒子を製造するための封入方法
Petersen et al. 64Cu loaded liposomes as positron emission tomography imaging agents
Soundararajan et al. [186Re] Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model
Edmonds et al. Exploiting the metal-chelating properties of the drug cargo for in vivo positron emission tomography imaging of liposomal nanomedicines
Phillips Delivery of gamma-imaging agents by liposomes
Psimadas et al. Molecular nanomedicine towards cancer: 111In‐labeled nanoparticles
Boerman et al. Radiolabeled liposomes for scintigraphic imaging
Engudar et al. Remote loading of liposomes with a 124I-radioiodinated compound and their in vivo evaluation by PET/CT in a murine tumor model
PL201398B1 (pl) System koniugatora radionuklid-liposom, sposób jego wytwarzania, zastosowanie systemu koniugatora do wytwarzania roztworu farmaceutycznego, zastosowanie terapeutyczne systemu koniugatora oraz zestaw do wytwarzania systemu koniugatora
Isaac-Olivé et al. [99mTc-HYNIC-N-dodecylamide]: a new hydrophobic tracer for labelling reconstituted high-density lipoproteins (rHDL) for radioimaging
Goins Radiolabeled lipid nanoparticles for diagnostic imaging
US20250135049A1 (en) Methods for Biological Material Labeling and Medical Imaging
TW201216992A (en) A kit for preparing a radiolabeled liposome and a method using the same
Laverman et al. Radiolabeling of liposomes for scintigraphic imaging
HK40008701B (en) Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
Gregory Radiolabeling of Liposomes for Scintigraphic Imaging
Andresen et al. Contribution of Nuclear Medicine to Cancer Nanotheranostics
Andresen et al. Anders E. Hansen* and Jonas R. Henriksent* Department of Micro-and Nanotechnology, Center for Nanomedicine and Theranostics, Technical University of Denmark
Christofi A dissertation research project

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141007

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141110

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151005

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20151030

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160113

R150 Certificate of patent or registration of utility model

Ref document number: 5872466

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees